Menu
Search
|

Menu

Close
X

Reata Pharmaceuticals Inc RETA.OQ (NASDAQ Stock Exchange Global Market)

60.14 USD
-- (--)
As of Nov 14
chart
Previous Close 60.14
Open --
Volume --
3m Avg Volume 124,425
Today’s High --
Today’s Low --
52 Week High 99.26
52 Week Low 19.32
Shares Outstanding (mil) 26.10
Market Capitalization (mil) 832.70
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
45
FY17
48
FY16
50
FY15
50
EPS (USD)
FY18
-1.999
FY17
-1.969
FY16
-0.289
FY15
-0.072
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
16.46
5.95
Price to Book (MRQ)
vs sector
--
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
--
17.74
LT Debt to Equity (MRQ)
vs sector
--
13.15
Return on Investment (TTM)
vs sector
-63.77
14.22
Return on Equity (TTM)
vs sector
--
15.99

EXECUTIVE LEADERSHIP

J. Warren Huff
Chairman of the Board, President, Chief Executive Officer, Since 2015
Salary: $514,000.00
Bonus: $385,500.00
Jason Wilson
Chief Financial Officer and Vice President, Strategy, Since 2015
Salary: --
Bonus: --
Dawn Bir
Vice President, Chief Commercial Officer, Since 2017
Salary: --
Bonus: --
Colin Meyer
Chief Medical Officer and Vice President, Product Development, Since
Salary: $400,000.00
Bonus: $200,000.00
Keith Ward
Vice President, Chief Development Officer, Since
Salary: $360,000.00
Bonus: $180,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2801 Gateway Dr Ste 150
IRVING   TX   75063

Phone: +1972.8652206

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.

SPONSORED STORIES